Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Nokia Corp (NOK) Price & Performance

Mesoblast LimitedTrade
Nokia CorpTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Nokia Corp — how do they compare? Mesoblast Limited trades at $14.33 (market cap $1.75B), while Nokia Corp trades at $10.35 (market cap $56.99B). The key difference: Nokia Corp is far larger — about 32.6× Mesoblast Limited's market cap, and Nokia Corp pays a 1.61% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Nokia Corp for 66 Days on average.

MESONOK
Market Cap
$1.75B$56.99B
Volume
239,02769,968,204
Sector
HealthTechnology
52-Week High
$20.96$16.83
52-Week Low
$13.19$5.18
Typical Hold Time
14 Days66 Days
Enterprise Value
$1.83B$55.01B
Dividend Yield
—1.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.

Nokia Corp

Nokia (NOK) trades at $10.62, down 3.19% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights a strategic partnership with Microsoft for AI-driven network automation and sovereign satellite network development with ICEYE, positioning Nokia for growth in AI and telecommunications infrastructure.

The outlook for Nokia is positive, supported by strong analyst consensus with a $17.50 price target and 61.5% buy ratings. Key opportunities include expanding AI and cloud orders, which grew 105% in Q2 2026. Risks involve competitive pressures in telecom equipment, reliance on global infrastructure spending, and volatility in net cash flow, which turned negative in 2025. Execution on partnerships and margin expansion are critical for sustained upside.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MESO

No sentiment data available yet.

NOK
80% Buy20% Sell
Avg holding period · 66 Days

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO →

About Nokia Corp

Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.

Read more on NOK →